Yeast fermentation technique allows researchers to isolate cannabinoids for treatment of different diseases.
New medical marijuana products produced by yeast could soon be on the market, the co-founder of a biotech company says. That could potentially lead to a wider range of cannabinoid-based drugs that proponents say could be more effective for treating certain medical conditions than medical marijuana itself.
Cannabinoids are chemical compounds found in marijuana. Kevin Chen’s Montreal-based company, Hyasynth, has successfully made the cannabinoid cannabigerol (CBG) from genetically engineered yeast, and he says this could be a precursor to other major and minor cannabinoids.
– Read the entire article at CBC News.
